FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease

FDA also approved a companion diagnostic device to select patients after cystectomy who have ctDNA molecular residual disease for adjuvant treatment

Source